{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:50:07Z","timestamp":1791467407784,"version":"4.3.4"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Potency testing and release of annual influenza vaccines require preparation, calibration, and distribution of reference antigens (RAs) and antisera every year, which takes an average of 8 to 12 weeks, and can be a major limiting factor in pandemic situations. Here we describe for the first time a robust Surface Plasmon Resonance (SPR)-based method that employs influenza subtype or lineage hemagglutinin (HA) specific monoclonal antibodies (mAbs) to measure the HA concentration in influenza multivalent vaccines. Implementing such an advanced test method will at the very least eliminate the rate-limiting and laborious efforts of making antisera reagents annually, and thus expedite the influenza vaccine delivery to the public by at least 6 weeks. Results demonstrate that the SPR-based method, developed using Biacore, is robust and not influenced by the type of RAs (inactivated whole virus, split, or subunit vaccine-derived materials), whether they are used as monovalent or multivalent preparations. HA concentrations obtained for monovalent drug substances (DS) or quadrivalent drug products (DP) of inactivated influenza split vaccine showed a tight correlation (the best fit value for the slope is 1.001 with R<jats:sup>2<\/jats:sup> of 0.9815 and P-value &amp;lt;0.0001) with the corresponding values obtained by the current potency assay, Single Radial Immunodiffusion (SRID). Supplementary analysis of the results by the Bland-Altman plot demonstrated good agreement between the SPR and SRID methods, with no consistent bias of the SPR versus SRID method. We further demonstrate that the SPR-based method can be used to estimate HA concentrations in intermediates of the influenza vaccine manufacturing process containing varying matrices and impurity levels. Further, the results demonstrate that the method is sensitive to detecting degradation of HA caused by elevated temperature, low pH, and freezing. It is evident from this report and other published work that the advancement of analytical techniques and the early findings are encouraging for the implementation of alternate potency assays with far-reaching benefits covering both seasonal and pandemic influenza.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1128683","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T05:07:45Z","timestamp":1688101665000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Rapid determination of influenza vaccine potency by an SPR-based method using subtype or lineage-specific monoclonal antibodies"],"prefix":"10.3389","volume":"14","author":[{"given":"Kartik","family":"Narayan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crina","family":"Paduraru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Blake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun B.","family":"Arunachalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)33293-2","article-title":"Estimates of global seasonal influenza-associated respiratory mortality: a modelling study","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet"},{"key":"B2","unstructured":"Fact-sheet. influenza (Seasonal)2018"},{"key":"B3","unstructured":"Weekly U.S. influenza surveillance report"},{"key":"B4","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0140-6736(17)30129-0","article-title":"Influenza","volume":"390","author":"Paules","year":"2017","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.12.018","article-title":"Global production capacity of seasonal and pandemic influenza vaccines in 2019","volume":"39","author":"Sparrow","year":"2021","journal-title":"Vaccine"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed","article-title":"Lessons learned: role of influenza vaccine production, distribution, supply, and demand\u2013what it means for the provider","author":"Orenstein","year":"2008","journal-title":"Am J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12383","article-title":"An overview of the regulation of influenza vaccines in the united states","volume":"10","author":"Weir","year":"2016","journal-title":"Influenza Other Respir Viruses"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1017\/S0022172400022610","article-title":"The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and b viruses","author":"Hobson","year":"1972","journal-title":"Epidemiol Infect"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir661","article-title":"And monto A.S. influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection","author":"Ohmit","year":"2011","journal-title":"J Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/irv.12543","article-title":"Standardisation of inactivated influenza vaccines-learning from history","author":"Wood","year":"2018","journal-title":"Influenza Other Respir Viruses"},{"key":"B11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1126\/science.94.2427.22","article-title":"The agglutination of red cells by allantoic fluid of chick embryos infected with influenza virus","volume":"94","author":"Hirst","year":"1941","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1084\/jem.79.2.185","article-title":"Quantitative aspects of the red blood cell agglutination test for influenza virus","volume":"79","author":"Miller","year":"1944","journal-title":"J Exp Med"},{"key":"B13","volume-title":"20th report of the WHO expert committee on biological standardization","year":"1968"},{"key":"B14","doi-asserted-by":"publisher","first-page":"S397","DOI":"10.1093\/infdis\/136.supplement_3.s397","article-title":"Correlation of laboratory studies with clinical responses to A\/New Jersey influenza vaccines","volume":"136","author":"Ennis","year":"1977","journal-title":"J Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"S731","DOI":"10.1093\/infdis\/136.supplement_3.s73","article-title":"And karzon D.T. trials of influenza A\/New Jersey\/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity","author":"Wright","year":"1977","journal-title":"J Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-1157(77)80008-5","article-title":"An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines","volume":"5","author":"Wood","year":"1977","journal-title":"J Biol Stand"},{"key":"B17","unstructured":"Note for guidance on harmonization of requirements for influenza vaccines1997"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1086\/590913","article-title":"An adjuvanted, low-dose, pandemic influenza a (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults","volume":"198","author":"Levie","year":"2008","journal-title":"J Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3390\/vaccines3010090","article-title":"Assaying the potency of influenza vaccines","volume":"3","author":"Minor","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"B20","unstructured":"Report to the President on reengineering the influenza vaccine production enterprise to meet the challenges of pandemic influenza2010"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.67","article-title":"Quantification of multivalent interactions between sialic acid and influenza a virus spike proteins by single-molecule force spectroscopy","volume":"142","author":"Cuellar-Camacho","year":"2020","journal-title":"J Am Chem Soc"},{"key":"B22","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nri.2016.67","article-title":"Combinatorial antibody libraries: new advances, new immunological insights","volume":"16","author":"Lerner","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/biom11030407","article-title":"And hufton S.E. broad reactivity single domain antibodies against influenza virus and their applications to vaccine potency testing and immunotherapy","volume":"11","author":"Tung Yep","year":"2011","journal-title":"Biomolecules"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12029","article-title":"Neutralizing and protective epitopes of the 2009 pandemic influenza H1N1 hemagglutinin","volume":"7","author":"Schmeisser","year":"2013","journal-title":"Influenza Other Respir Viruses."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117108","article-title":"Antibodies to antigenic site a of influenza H7 hemagglutinin provide protection against H7N9 challenge","volume":"28","author":"Schmeisser","year":"2015","journal-title":"PloS One"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175733","article-title":"Determination of influenza b identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific monoclonal antibodies","volume":"12","author":"Verma","year":"2017","journal-title":"PloS One"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.10.070","article-title":"A novel assay for influenza virus quantification using surface plasmon resonance","volume":"28","author":"Nilsson","year":"2010","journal-title":"Vaccine"},{"key":"B28","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1750-2659.2012.00375.x","article-title":"Development of an enzyme-linked immunoassay for the quantitation of influenza haemagglutinin: an alternative method to single radial immunodiffusion","volume":"7","author":"Bodle","year":"2013","journal-title":"Influenza Other Respir Viruses"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055428","article-title":"A novel synthetic receptor-based immunoassay for influenza vaccine quantification","volume":"8","author":"Hashem","year":"2013","journal-title":"PloS One"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.02.049","article-title":"Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency","volume":"32","author":"Khurana","year":"2014","journal-title":"Vaccine"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109616","article-title":"And rowlen K.L. titer on chip: new analytical tool for influenza vaccine potency determination","volume":"9","author":"Kuck","year":"2014","journal-title":"PloS One"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12272","article-title":"A monoclonal antibody-based immunoassay for measuring the potency of 2009 pandemic influenza H1N1 vaccines","volume":"8","author":"Schmeisser","year":"2014","journal-title":"Influenza Other Respir Viruses"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.01.083","article-title":"SPRi-based hemagglutinin quantitative assay for influenza vaccine production monitoring","volume":"37","author":"Durous","year":"2019","journal-title":"Vaccine"},{"key":"B34","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ab.2016.06.024","article-title":"Comparison of biosensor platforms in the evaluation of high affinity antibody-antigen binding kinetics","volume":"508","author":"Yang","year":"2016","journal-title":"Anal Biochem"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00700-11","article-title":"And crowe J.E. jr. a broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin","volume":"85","author":"Krause","year":"2011","journal-title":"J Virol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-621-0_9","article-title":"Influenza virus surveillance, vaccine strain selection, and manufacture","volume":"865","author":"St\u00f6hr","year":"2012","journal-title":"Methods Mol Biol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12365","article-title":"A novel approach for preparation of the antisera reagent for potency determination of inactivated H7N9 influenza vaccines","volume":"10","author":"Schmeisser","year":"2016","journal-title":"Influenza Other Respir Viruses"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(91)90331-9","article-title":"Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system","volume":"145","author":"Karlsson","year":"1991","journal-title":"J Immunol Methods"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1177\/096228029900800204","article-title":"And altman D.G. measuring agreement in method comparison studies","volume":"8","author":"Bland","year":"1999","journal-title":"Stat Methods Med Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01388-13","article-title":"Antibody recognition of the pandemic H1N1 influenza virus hemagglutinin receptor binding site","volume":"87","author":"Hong","year":"2013","journal-title":"J Virol"},{"key":"B41","unstructured":"Recommended composition of influenza virus vaccines for use in the 2021 southern hemisphere influenza season2020"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.02.028","article-title":"And rowlen K.L. VaxArray assessment of influenza split vaccine potency and stability","volume":"35","author":"Kuck","year":"2017","journal-title":"Vaccine"},{"key":"B43","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41541-021-00403-7","article-title":"Unique features of a recombinant haemagglutinin influenza vaccine that influence vaccine performance","volume":"6","author":"Arunachalam","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.06.051","article-title":"Assessing the stability-indicating properties of alternative potency assays for inactivated influenza vaccine","author":"Ekimov","year":"2023","journal-title":"Vaccine"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1128683\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T05:07:49Z","timestamp":1688101669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1128683\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":44,"alternative-id":["10.3389\/fimmu.2023.1128683"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1128683","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,29]]},"article-number":"1128683"}}